Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
BCL6 inhibitors and degraders act on B-cell lymphoma 6 (BCL6), a transcriptional repressor in B cells. The BCL6 gene was first identified through chromosomal alterations in diffuse large B-cell lymphoma (DLBCL), and BCL6 is required for germinal center B cells. A small molecule that blocks BCL6 repressor activity was shown to kill DLBCL cells in vitro and in vivo, which made the protein a research target in lymphoma. Listed inhibitors include FX1 and BI-3812, while BI-3802 and the proteolysis-targeting chimera (PROTAC) ARV-393 lower BCL6 protein levels. The section also holds molecular glues such as TCIP3 and building blocks for degrader synthesis.
3-Fluoro-desmethyl-cabozantinib is a selective ligand for the BCL6 protein, facilitating targeted protein degradation through PROTAC technology. It serves as an essential building block in the development of innovative therapeutics aimed at modulating protein levels for various cancer applications. This compound may enhance research into BCL6-related pathways and assist in the design of more effective treatments.
Out of stock
All 3 sizes
Synonyms: BAK-04-212
EB-TCIP is an EWSR1::FLI1 binder that operates by forming a ternary complex with the tagged fusion protein BCL6 and FKBP12F36V. This compound specifically recruits the EWSR1::FLI1 fusion to BCL6-associated DNA regions, leading to chromatin remodeling and the relocalization of transcriptional factors. As a result, EB-TCIP activates the expression of previously repressed BCL6 target genes. It serves as a valuable tool in the exploration of innovative epigenetic therapies for Ewing sarcoma.
BCL6 ligand-4 is a selective ligand targeting BCL6, a key regulator of oncogenic transcription. This compound is primarily utilized in the synthesis of PROTACs, enabling targeted protein degradation for therapeutic applications in oncology research. BCL6 ligand-4 provides researchers with essential tools to explore BCL6-related pathways and develop innovative cancer treatments.
Out of stock
All 3 sizes
BCL6 ligand-5 is a selective ligand for the BCL6 protein, involved in transcriptional regulation and oncogenesis. This compound serves as a crucial component for the development of PROTAC-based degraders targeting BCL6, such as PROTAC BCL6 Degrader-2. Additionally, BCL6 ligand-5 has applications in tumor research, contributing to the study of cancer biology and therapeutic strategies.
Out of stock
All 3 sizes
EN171 is a covalent ligand that selectively modifies cysteine residues C38 and C96 on the 14-3-3 protein, thereby promoting its interactions with estrogen receptor α (ERα), YAP, and TAZ. This modulation leads to a reduction in transcriptional activity associated with both estrogen signaling and the Hippo pathway. EN171 serves as a molecular glue, enhancing native protein interactions, and acts as a covalent recruiter of 14-3-3 in heterobifunctional applications, facilitating the cytosolic sequestering of nuclear neo-substrates such as BRD4 and BCL6.
